Form 4: MAIA Biotechnology Director Stan Smith Acquires Shares and Warrants

Director Stan Smith purchased 50,000 shares of MAIA Biotechnology and related warrants, increasing his indirect beneficial ownership.

Summary

• On February 24, 2025, Stan Smith, a director of MAIA Biotechnology, acquired 50,000 shares of common stock at $1.50 per share.
• The purchase was made pursuant to a Securities Purchase Agreement and issued under the Issuer's 2021 Equity Incentive Plan.
• Smith also acquired warrants to purchase 50,000 shares of common stock at an exercise price of $1.87.
• These warrants were also purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan.
• The options are exercisable beginning on August 24, 2025, and expire on August 24, 2030.
• Following the transaction, Smith's indirect beneficial ownership totals 1,180,060 shares of common stock and 50,000 warrants, held through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the overall impact depends on the size of the purchase relative to the director's existing holdings and the company's market capitalization.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director share purchases are common in the biotechnology industry and are often viewed as a sign of confidence in the company's prospects. The market will likely interpret this Form 4 filing in light of MAIA Biotechnology's current clinical trials and overall financial health.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The purchase has a limited impact on employees, customers, suppliers, and creditors.

Key Dates